Deaths / year
2,000
GBD (indicative unless refreshed)
DALYs / year
1,900,000
GBD
Pathogen
Helminth
Post-infectious
Chronic disease
Persistent symptoms
n/a
Post-infectious syndrome & persistent symptoms
Whether a post-acute infection syndrome is documented and the literature proportion with persistent symptoms.
Post-acute status
Chronic biliary disease; cholangiocarcinoma (Opisthorchis/Clonorchis)
Classification
Chronic disease
Onset
chronic/late
Persistent-symptom %
not quantified as a single figure (see notes)
Source: IARC group-1 carcinogen; WHO
Therapeutic agents by stage
Vector control, prevention, acute treatment, and post-infectious care. Only agents with published evidence are shown by default.
Prevention
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Food safety & cooking education | Prevention | Approved | Prevent raw-fish / aquatic plant ingestion | WHO EML / standard of care |
Acute phase
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Praziquantel | Anthelmintic | Approved | Opisthorchiasis, clonorchiasis, paragonimiasis | WHO EML / standard of care |
| Triclabendazole | Anthelmintic | Approved | Fascioliasis (liver fluke) | WHO EML / standard of care |
Post-infectious phase
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Cholangiocarcinoma surveillance (Opisthorchis/Clonorchis) | Oncology follow-up | Approved | Chronic biliary sequelae | IARC; WHO |
Associated drug targets (Open Targets): EGFR, SERPINA1, S100A8, PTGS2, TLR2, GRN
Burden: IHME GBD (indicative seed unless refreshed) · Therapeutics: curated WHO EML / SOC + Open Targets pipeline · Post-infectious data: curated peer-reviewed literature · Ontology: MONDO_0005884 · Updated 2026-07-10. Associations, not a diagnostic test.